Jacob Bell
New Member
Perugia, Italy: Patients with a history of migraine headaches may be suffering from a clinical deficiency of the
endocannabinoid system, according to clinical trial data published in the European Journal of Clinical Pharmacology.
Investigators at Italy's University of Perugia, Department of Public Health, reported that patients with chronic migraines
possessed "significantly lower" levels of the endogenous cannabinoids anandamide and 2-arachidonylglycerol (2-AG) in
their platelets compared to age-matched controls.
"These data support the potential involvement of a dysfunctioning of the endocannabinoid and serotonergic systems in
the pathology of chronic migraine and medication-overuse headaches," researchers' concluded.
A previous paper published in the journal Neuroendocrinology Letters similarly suggested that migraine, fibromyalgia,
and other treatment-resistant conditions may be associated with dysfunctions in the endocannabinoid system. This
system is believed to play a primary role in regulating humans' mood, appetite, skeletal development, motor
coordination, digestion, and reproduction.
Full text of the study: "Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache
patients: relation with serotonin levels," European Journal of Clinical Pharmacology, November 2007:
SpringerLink - European Journal of Clinical Pharmacology, Volume 64, Number 1
Anandamide: Anandamide - Wikipedia, the free encyclopedia
"The Endocannabinoid System: Physiology and Pharmacology" :
THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
"Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine,
Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions?"
<i>Abstract</i>: Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions?
Source: Migraine May Be Related To Underproduction Of Cannabinoids, Study Says
endocannabinoid system, according to clinical trial data published in the European Journal of Clinical Pharmacology.
Investigators at Italy's University of Perugia, Department of Public Health, reported that patients with chronic migraines
possessed "significantly lower" levels of the endogenous cannabinoids anandamide and 2-arachidonylglycerol (2-AG) in
their platelets compared to age-matched controls.
"These data support the potential involvement of a dysfunctioning of the endocannabinoid and serotonergic systems in
the pathology of chronic migraine and medication-overuse headaches," researchers' concluded.
A previous paper published in the journal Neuroendocrinology Letters similarly suggested that migraine, fibromyalgia,
and other treatment-resistant conditions may be associated with dysfunctions in the endocannabinoid system. This
system is believed to play a primary role in regulating humans' mood, appetite, skeletal development, motor
coordination, digestion, and reproduction.
Full text of the study: "Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache
patients: relation with serotonin levels," European Journal of Clinical Pharmacology, November 2007:
SpringerLink - European Journal of Clinical Pharmacology, Volume 64, Number 1
Anandamide: Anandamide - Wikipedia, the free encyclopedia
"The Endocannabinoid System: Physiology and Pharmacology" :
THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
"Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine,
Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions?"
<i>Abstract</i>: Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions?
Source: Migraine May Be Related To Underproduction Of Cannabinoids, Study Says
